無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

抗真菌剤市場分析:薬剤クラス別 (アゾール、エキノカンジン、ポリエン、アリルアミン)、適応別 (皮膚糸状菌症、アスペルギルス症、カンジダ症) のセグメント予測

Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis), and Segment Forecasts, 2018 - 2025

発行 Grand View Research, Inc. 商品コード 408955
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.44円で換算しております。
Back to Top
抗真菌剤市場分析:薬剤クラス別 (アゾール、エキノカンジン、ポリエン、アリルアミン)、適応別 (皮膚糸状菌症、アスペルギルス症、カンジダ症) のセグメント予測 Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis), and Segment Forecasts, 2018 - 2025
出版日: 2018年12月11日 ページ情報: 英文 100 Pages
概要

当レポートでは、世界の抗真菌剤市場について調査し、市場の動向、薬剤クラス別、適応別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 調査方法

第2章 エグゼクティブサマリー

第3章 市場の変動、動向、範囲

  • 市場セグメンテーション
    • 促進因子分析
    • 阻害因子分析
  • 浸透・成長見通しマッピング
  • PESTLE分析
  • 業界分析:ポーターズ

第4章 薬剤クラス別予測・動向分析

  • 薬剤クラス別動向分析
  • アゾール
  • エキノカンジン
  • ポリエン
  • アリルアミン
  • その他

第5章 適応別予測・動向分析

  • 適応別動向分析
  • 皮膚糸状菌症
  • アスペルギルス症
  • カンジダ症
  • その他

第6章 地域別予測・動向分析

  • 地域別市場シェア
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第7章 競合環境

  • 戦略枠組み
  • 市場参入分類
  • 企業プロファイル
図表

List of Tables

  • TABLE 1 Azole antifungal drugs market, by type, 2014 - 2025 (USD Million)
  • TABLE 2 Echinocandins antifungal drugs market, by type, 2014 - 2025 (USD Million)
  • TABLE 3 Polyenes antifungal drugs market, by type, 2014 - 2025 (USD Million)
  • TABLE 4 Allylamines antifungal drugs market, by type, 2014 - 2025 (USD Million)
  • TABLE 5 North America antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 6 North America antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 7 U.S. antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 8 U.S. antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 9 Canada antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 10 Canada antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 11 Europe antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 12 Europe antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 13 U.K. antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 14 U.K. antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 15 Germany antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 16 Germany antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 17 Asia Pacific antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 18 Asia Pacific antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 19 Japan antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 20 Japan antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 21 China antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 22 China antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 23 India antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 24 India antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 25 Latin America antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 26 Latin America antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 27 Brazil antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 28 Brazil antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 29 Mexico antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 30 Mexico antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 31 MEA antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 32 MEA antifungal drugs market, by indications, 2014 - 2025 (USD Million)
  • TABLE 33 South Africa antifungal drugs market, by class, 2014 - 2025 (USD Million)
  • TABLE 34 South Africa antifungal drugs market, by indications, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Penetration & Growth Prospect Mapping
  • FIG. 7 Antifungal Drugs SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 8 Porter's Five Forces Analysis
  • FIG. 9 Antifungal drugs market class outlook key takeaways
  • FIG. 10 Antifungal drugs market: Drug class movement analysis
  • FIG. 11 Azoles market, 2014 - 2025 (USD Million)
  • FIG. 12 Echinocandins market, 2014 - 2025 (USD Million)
  • FIG. 13 Polyenes market, 2014 - 2025 (USD Million)
  • FIG. 14 Allylamines market, 2014 - 2025 (USD Million)
  • FIG. 15 Others market, 2014 - 2025 (USD Million)
  • FIG. 16 Antifungal drugs market indication outlook key takeaways
  • FIG. 17 Antifungal drugs market: Indications movement analysis
  • FIG. 18 Dermatophytosis market, 2014 - 2025 (USD Million)
  • FIG. 19 Aspergillosis market, 2014 - 2025 (USD Million)
  • FIG. 20 Candidiasis market, 2014 - 2025 (USD Million)
  • FIG. 21 Invasive candidiasis market, 2014 - 2025 (USD Million)
  • FIG. 22 VVC market, 2014 - 2025 (USD Million)
  • FIG. 23 Mouth/throat/esophageal candidiasis market, 2014 - 2025 (USD Million)
  • FIG. 24 Other candidal infections market, 2014 - 2025 (USD Million)
  • FIG. 25 Others market, 2014 - 2025 (USD Million)
  • FIG. 26 Regional market place: Key takeaways
  • FIG. 27 Regional outlook, 2017 & 2025
  • FIG. 28 North America antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 29 U.S. antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 30 Canada antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 31 Europe antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 32 U.K. antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 33 Germany antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 34 Asia Pacific antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 35 Japan antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 36 China antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 37 India antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 38 Latin America antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 39 Brazil antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 40 Mexico antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 41 MEA antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 42 South Africa antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 43 Strategy framework
  • FIG. 44 Participant categorization
目次
Product Code: GVR-1-68038-293-8

The global antifungal drugs market size is expected to reach USD 12.7 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 1.5% during the forecast period. Increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, rise in adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in increased incidence of fungal infections in recent years.

According to statistics published by the Centers of Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to high prevalence of mycological infections around the globe.

As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, rise in geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2025 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Further key findings from the study suggest:

Several types of fungicidal preparations, such as creams, sprays, tablets, & injections, are available. Increasing adoption of these products is anticipated to drive the market during the forecast period

The echinocandins segment is anticipated to exhibit lucrative growth owing to their cell wall-specific fungicidal property coupled with their broad-spectrum activity against Aspergillus and Candida species without cross-resistance risks

The candidiasis indication segment is expected to witness the fastest CAGR over the forecast period due to increasing drug resistance of the Candida species to Azoles

North America held the largest market share in 2017. The growth of the market can be attributed to higher awareness levels pertaining to treatment of fungal infection and presence of a large target population

Asia pacific is projected to register the fastest growth during the forecast period due to improving healthcare facilities coupled with rising government initiatives to create awareness of infectious diseases among the population

Companies are focusing on development of effective therapeutic agents for treatment of systemic fungal infections in immune-compromised patients

Numerous ongoing public-private partnership agreements in the pharmaceutical industry for development of novel therapeutics is poised to provide the market with lucrative growth opportunities. For instance, Astellas Pharma partnered with Vical Incorporated for the development of VL-2397, an antifungal drug for the treatment of pulmonary aspergillus.

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Region Wise Market Calculation
    • 1.1.1 Region Wise Market: Base Estimates
    • 1.1.2 Country share estimation
    • 1.1.3 Global Market: CAGR Calculation
  • 1.2 Region based segment share calculation
  • 1.3 List of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Antifungal Drugs Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Increasing incidence of fungal infections
    • 3.2.2 Rising R & D pertaining to the development of novel drugs
    • 3.2.3 Increase in awareness
  • 3.3 Market Restraint Analysis
    • 3.3.1 Increasing resistance to antifungal drugs
    • 3.3.2 Presence of generic competition
  • 3.4 Penetration & Growth Prospect Mapping
  • 3.5 Antifungal Drugs - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.6 Industry Analysis - Porter's
  • 3.7 Pricing Analysis
  • 3.8 Competitive Landscape
  • 3.9 Pipeline Analysis

Chapter 4 Antifungal Drugs Market Drug Class Estimates & Trend Analysis

  • 4.1 Antifungal Drugs Market: Drug Class Movement Analysis
  • 4.2 Azoles
    • 4.2.1 Azoles market, 2014 - 2025 (USD Million)
    • 4.2.2. Voriconazole (Vfend)
      • 4.2.1.1 Voriconazole (Vfend) market, 2014 - 2025 (USD Million)
    • 4.2.3 Posaconazole (Noxafil)
      • 4.2.3.1 Posaconazole (Noxafil) market, 2014 - 2025 (USD Million)
    • 4.2.4 Posaconazole (Noxafil)
      • 4.2.4.1 Clotrimazole (Canesten) market, 2014 - 2025 (USD Million)
    • 4.2.5 Isavuconazole (CRESEMBA)
      • 4.2.5.1 Isavuconazole (CRESEMBA) market, 2014 - 2025 (USD Million)
    • 4.2.6 Isavuconazole (CRESEMBA)
      • 4.2.6.1 Others market, 2014 - 2025 (USD Million)
  • 4.3 Echinocandins
    • 4.3.1 Echinocandins market, 2014 - 2025 (USD Million)
    • 4.3.2 Caspofungin (Cancidas)
      • 4.3.2.1 Caspofungin (Cancidas) market, 2014 - 2025 (USD Million)
    • 4.3.3 Micafungin (Mycamine/ Funguard)
      • 4.3.3.1 Micafungin (Mycamine/ Funguard) market, 2014 - 2025 (USD Million)
    • 4.3.4 Others
      • 4.3.4.1 Others market, 2014 - 2025 (USD Million)
  • 4.4 Polyenes
    • 4.4.1 Polyenes market, 2014 - 2025 (USD Million)
    • 4.4.2 Amphotericin (AmBisome)
      • 4.4.2.1 Amphotericin (AmBisome) market, 2014 - 2025 (USD Million)
    • 4.4.3 Others
      • 4.4.3.1 Others market, 2014 - 2025 (USD Million)
  • 4.5 Allylamines
    • 4.5.1 Allylamines market, 2014 - 2025 (USD Million)
    • 4.5.2 Terbinafine (Lamisil)
      • 4.5.2.1 Terbinafine (Lamisil) market, 2014 - 2025 (USD Million)
    • 4.5.3 Others
      • 4.5.3.1 Others market, 2014 - 2025 (USD Million)
  • 4.6 Others
    • 4.6.1 Others market, 2014 - 2025 (USD Million)

Chapter 5 Antifungal Drugs Market Indication Estimates & Trend Analysis

  • 5.1 Antifungal Drugs Market: Indication Movement Analysis
  • 5.2 Dermatophytosis
    • 5.2.1 Dermatophytosis market, 2014 - 2025 (USD Million)
  • 5.3 Aspergillosis
    • 5.3.1 Aspergillosis market, 2014 - 2025 (USD Million)
  • 5.4 Candidiasis
    • 5.4.1 Candidiasis market, 2014 - 2025 (USD Million)
    • 5.4.2 Invasive Candidiasis
      • 5.4.2.1 Invasive candidiasis market, 2014 - 2025 (USD Million)
    • 5.4.3 Vulvovaginal Candidiasis (VVC)
      • 5.4.3.1 VVC market, 2014 - 2025 (USD Million)
    • 5.4.4 Mouth/Throat/Esophageal Candidiasis
      • 5.4.4.1 Mouth/throat/esophageal candidiasis market, 2014 - 2025 (USD Million)
    • 5.4.5 Other candida infections
      • 5.4.5.1 Other candidal infections market, 2014 - 2025 (USD Million)
  • 5.5 Others
    • 5.5.1 Others market, 2014 - 2025 (USD Million)

Chapter 6 Antifungal Drugs Market Regional Estimates & Trend Analysis, by Drug Class and Indications

  • 6.1 Antifungal drugs market share by region, 2017 & 2025
  • 6.2 North America
    • 6.2.1 North America antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 U.S. antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Canada antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.3.2 U.K.
      • 6.3.2.1 U.K. antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Germany antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Japan antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 China antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 India antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Brazil antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Mexico antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.6 MEA
    • 6.6.1 MEA antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 South Africa antifungal drugs market, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy Framework
  • 7.2 Market Participation Categorization
  • 7.3 Company Profiles
    • 7.3.1 Novartis AG
      • 7.3.1.1 Company overview
      • 7.3.1.2 Financial performance
      • 7.3.1.3 Product benchmarking
      • 7.3.1.4 Strategic initiatives
    • 7.3.2 Pfizer, Inc.
      • 7.3.2.1 Company overview
      • 7.3.2.2 Financial performance
      • 7.3.2.3 Product benchmarking
      • 7.3.2.4 Strategic initiatives
    • 7.3.3 Bayer AG
      • 7.3.3.1 Company overview
      • 7.3.3.2 Financial performance
      • 7.3.3.3 Product benchmarking
      • 7.3.3.4 Strategic initiatives
    • 7.3.4 Sanofi
      • 7.3.4.1 Company overview
      • 7.3.4.2 Financial performance
      • 7.3.4.3 Product benchmarking
    • 7.3.5 Merck & Co., Inc.
      • 7.3.5.1 Company overview
      • 7.3.5.2 Financial performance
      • 7.3.5.3 Product benchmarking
      • 7.3.5.4 Strategic initiatives
    • 7.3.6 GlaxoSmithKline plc
      • 7.3.6.1 Company overview
      • 7.3.6.2 Financial performance
      • 7.3.6.3 Product benchmarking
      • 7.3.6.4 Strategic initiatives
    • 7.3.7 Abbott
      • 7.3.7.1 Company overview
      • 7.3.7.2 Financial performance
      • 7.3.7.3 Product benchmarking
      • 7.3.7.4 Strategic initiatives
    • 7.3.8 Glenmark
      • 7.3.8.1 Company overview
      • 7.3.8.2 Financial performance
      • 7.3.8.3 Product benchmarking
      • 7.3.8.4 Strategic initiatives
    • 7.3.9 Enzon Pharmaceuticals, Inc.
      • 7.3.9.1 Company overview
      • 7.3.9.2 Financial performance
      • 7.3.9.3 Product benchmarking
    • 7.3.10 Astellas Pharma, Inc.
      • 7.3.10.1 Company overview
      • 7.3.10.2 Financial performance
      • 7.3.10.3 Product benchmarking
      • 7.3.10.4 Strategic initiatives
Back to Top